Celiprolol in angina pectoris.

Area of Science:

• Cardiology
• Pharmacology

Background:

• Celiprolol is a long-acting beta-blocker with selective beta1-adrenergic blocking properties.
• It possesses unique peripheral beta2-stimulatory and alpha2-inhibitory activities, contributing to a vasodilator profile.

Purpose of the Study:

• To evaluate the efficacy and safety of celiprolol in patients with angina pectoris.
• To compare the hemodynamic properties and antianginal effects of celiprolol with traditional beta-blockers.

Main Methods:

• Multiple studies were conducted to assess celiprolol's antianginal effects.
• Comparative analyses were performed against placebo, propranolol, and atenolol.

Main Results:

• Celiprolol demonstrated significant efficacy as an antianginal agent compared to placebo.
• Its effectiveness in managing angina and ischemia was found to be comparable to propranolol and atenolol.

Conclusions:

• Celiprolol is an effective treatment option for angina pectoris.
• Its unique pharmacologic profile offers distinct hemodynamic advantages over traditional beta-blockers.